<DOC>
	<DOCNO>NCT00004010</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Radiation therapy use high-energy x-rays damage cancer cell . Giving radiation therapy chemotherapy may effective treatment Hodgkin 's disease . PURPOSE : Phase II trial study effectiveness combination chemotherapy radiation therapy treat child previously untreated stage II , stage III , stage IV Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Children With Previously Untreated Stage II , Stage III , Stage IV Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility toxicity bleomycin , etoposide , doxorubicin , cyclophosphamide , vincristine , procarbazine , prednisone ( BEACOPP ) induction pediatric patient previously untreated stage II , stage III , stage IV Hodgkin 's disease . II . Determine rate complete response rapid early partial response ( define great 70 % reduction size bulky mediastinal mass nodal aggregate negative gallium scan ) patient treat 4 course BEACOPP . III . Determine whether thallium scan effectively measure response therapy patient treat regimen . IV . Evaluate expression marker apoptosis tumor sample patient diagnosis time relapse , correlate expression marker response therapy overall outcome . V. Determine utility seven molecular genetic marker surrogate marker genotoxic damage cause regimen patient . VI . Estimate incidence therapy relate late effect , include second malignant neoplasm , sterility , cardiac dysfunction , pulmonary restrictive disease , growth abnormality , thyroid disease patient . OUTLINE : Induction : On day 0 , patient receive cyclophosphamide IV 30 minute , doxorubicin IV 15-30 minute , etoposide IV 1 hour , oral prednisone every 12 hour , oral procarbazine . On day 1 2 , patient receive etoposide IV 1 hour , oral prednisone every 12 hour , oral procarbazine . On day 3-6 , patient receive oral prednisone every 12 hour oral procarbazine . On day 7 , patient receive vincristine IV , bleomycin IV 5 minute , oral prednisone every 12 hour . On day 8-13 , patient receive oral prednisone every 12 hour . Beginning day 8 , patient receive filgrastim ( G-CSF ) subcutaneously absolute neutrophil count recover . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Consolidation therapy begin week 12 blood count recover . Consolidation rapid early responder ( patient complete response ( CR ) rapid early partial response ( PR-1 ) induction therapy ) : Females - Patients receive vincristine IV , cyclophosphamide IV 30 minute , oral prednisone every 12 hour , oral procarbazine day 0 . On day 1-6 , patient receive oral prednisone every 12 hour oral procarbazine . On day 7 , patient receive vinblastine IV , bleomycin IV 5 minute , doxorubicin IV 15-30 minute , oral prednisone every 12 hour . On day 8-13 , patient receive oral prednisone every 12 hour . Treatment repeat every 28 day total 4 course absence disease progression unacceptable toxicity . Males - Patients receive doxorubicin IV 15-30 minute , bleomycin IV 5 minute , vinblastine IV , dacarbazine IV day 0 14 . Treatment repeat every 28 day total 2 course absence disease progression unacceptable toxicity . Beginning 3 week completion chemotherapy , male patient CR PR-1 receive radiotherapy 5 day per week area initial disease involvement ( total duration radiotherapy dependent initial extent disease ) . Consolidation slow early responder : Patients slow partial response ( PR-2 ) stable disease ( SD ) 4 course induction therapy receive 4 additional course induction therapy absence disease progression unacceptable toxicity . Beginning day 8 , patient receive G-CSF subcutaneously blood count recover . Patients G-CSF 24 hour prior next course chemotherapy . Beginning 3 week completion chemotherapy , male female patient PR-2 SD receive radiotherapy 5 day per week area initial disease involvement ( total duration radiotherapy dependent initial extent disease ) . Patients follow every 3 month 2 year , every 6 month 1 year , annually 2 year year 10 20 . PROJECTED ACCRUAL : Approximately 25-50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , previously untreated Hodgkin 's disease Stage IV OR Stage II stage III B symptom ( least 1 follow : unexplained weight loss great 10 % , unexplained recurrent fever great 39 degree C , drench night sweat ) AND bulk disease ( defined mediastinal mass great 1/3 mediastinal thoracic diameter and/or nodal aggregate great 10.0 cm ) The follow cellular type eligible : Mixed cellularity , otherwise specify ( NOS ) Lymphocytic depletion , NOS Lymphocytic depletion , diffuse fibrosis Lymphocytic depletion , reticular Lymphocytic predominance , NOS Lymphocytic predominance , diffuse Lymphocytic predominance , nodular Hodgkin 's paragranuloma Hodgkin 's granuloma Hodgkin 's sarcoma Nodular sclerosis , NOS Nodular sclerosis , cellular phase Nodular sclerosis , lymphocytic predominance Nodular sclerosis , mixed cellularity Nodular sclerosis , lymphocytic depletion Hodgkin 's disease , NOS Must begin protocol therapy within 42 day biopsy 7 day completion stag PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior treatment Hodgkin 's disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte predominant Hodgkin lymphoma</keyword>
	<keyword>childhood lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>childhood nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>childhood mixed cellularity Hodgkin lymphoma</keyword>
</DOC>